|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 217/02 | |
| C07D 217/24 | |||
| C07D 401/12 | |||
| C07D 409/12 | |||
| C07D 417/12 | |||
| C07C 237/00 | |||
| A61P 27/00 | |||
| A61K 31/33 | |||
| A61K 31/47 |
| (11) | Number of the document | 3354643 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18160338.2 |
| Date of filing the European patent application | 2010-01-27 | |
| (97) | Date of publication of the European application | 2018-08-01 |
| (45) | Date of publication and mention of the grant of the patent | 2020-10-28 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 174672 P | 2009-05-01 | US |
| (72) |
deLong, Mitchell A., US
Sturdivant, Jill Marie, US
Royalty, Susan M., US
|
| (73) |
Aerie Pharmaceuticals, Inc.,
550 Hills Drive, Third Floor, Bedminster, NJ 07921,
US
|
| (54) | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE |
| DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE |